AUR-AFEC-TTM4-A-1-1-R-A742-41
— · C
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- C
- subtype
- C
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.690
- COAGULATION+0.630
- XENOBIOTIC_METABOLISM+0.630
- FATTY_ACID_METABOLISM+0.550
- OXIDATIVE_PHOSPHORYLATION+0.550
- BILE_ACID_METABOLISM+0.540
- HYPOXIA+0.500
- GLYCOLYSIS+0.480
- TNFA_SIGNALING_VIA_NFKB+0.470
- ANGIOGENESIS+0.450
Top 10 suppressed
- MITOTIC_SPINDLE-0.240
- WNT_BETA_CATENIN_SIGNALING-0.240
- UV_RESPONSE_DN-0.200
- G2M_CHECKPOINT-0.150
- NOTCH_SIGNALING-0.070
- PROTEIN_SECRETION-0.060
- E2F_TARGETS-0.050
- SPERMATOGENESIS-0.010
- MYC_TARGETS_V2+0.020
- UNFOLDED_PROTEIN_RESPONSE+0.020
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
6 twins match this tumor's tissue · 4 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SNU878_LIVER | HCC | — | 0.881 |
| 2 | SRR1335688 | GTEX | — | 0.876 |
| 3 | SRR1347688 | GTEX | — | 0.875 |
| 4 | SRR35579831 | — | C | 0.874 |
| 5 | SRR1374414 | GTEX | — | 0.864 |
| 6 | SRR15030876 | — | — | 0.860 |
| 7 | TCGA-39-5039-01A-01R-1443-07 | — | cohortSQ1 | 0.860 |
| 8 | TCGA-XF-A9SJ-01A-11R-A39I-07 | — | — | 0.856 |
| 9 | SRR3147741 | — | — | 0.855 |
| 10 | 349c48ca-ced2-42db-8a50-ea3293116623 | — | — | 0.852 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 42 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.690 | Inavolisib | — uncovered |
| COAGULATION | 0.630 | Binimetinib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.630 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.550 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.550 | Remibrutinib | — uncovered |
| BILE_ACID_METABOLISM | 0.540 | Inavolisib | — uncovered |
| HYPOXIA | 0.500 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.480 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.470 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.450 | Remibrutinib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.450 | Remibrutinib | — uncovered |
| ADIPOGENESIS | 0.440 | Inavolisib | — uncovered |
| PEROXISOME | 0.420 | Idelalisib | — uncovered |
| COMPLEMENT | 0.410 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.400 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.370 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.320 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.320 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.310 | Inavolisib | — uncovered |
| APOPTOSIS | 0.300 | Idelalisib | — uncovered |